Clinical Trials Directory

Trials / Completed

CompletedNCT06332456

Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography

Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography: A Proof-of-Concept Study

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Matthieu Pelletier-Galarneau, MD MSc · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

The aim of this study is to demonstrate that positron emission tomography imaging with Rubidium-82 (radioactive tracer) can non-invasively detect and quantify changes in renal blood flow (renal perfusion) and renal vascular resistance in both healthy subjects and patients with renal insufficiency. Ultimately, the results of this study will contribute to a better understanding of the role of positron emission imaging in the evaluation of patients with renal diseases.

Detailed description

2\. Hypothesis 1. We hypothesize that RBF assessed with rubidium PET is on average lower in patients with CKD. To test our hypothesis, RBF of patients with CKD and coronary artery disease (CAD) risk factors, a population characterized by renal microvascular rarefaction, will be compared to RBF of healthy controls. 2. We hypothesize that RVR assessed with rubidium PET correlates with echographic measurements of renal resistance index (RI), the current non-invasive method of choice. 3. We hypothesize that RBF quantification with rubidium PET is technically reproducible, meaning that the variation on the measurements of RBF purely attributable to technical factors (camera, positioning, tracer injection, etc.) is relatively small. To test this hypothesis, two PET scans will be acquired within a short time period. 3\. Objectives and Endpoints 3.1. Primary Objective 1\) To compare RBF of patients with CKD and CAD risk factors to healthy controls 3.2. Secondary Objectives 1. To compare RVR of patients with CKD and CAD risk factors to healthy controls 2. To evaluate the correlation between RVR measured with PET to renal RI as measured with echography 3. To evaluate the repeatability and reproducibility of in vivo measurements of RBF and RVR

Conditions

Timeline

Start date
2023-07-04
Primary completion
2024-11-21
Completion
2024-11-22
First posted
2024-03-27
Last updated
2025-07-29

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06332456. Inclusion in this directory is not an endorsement.